Hot Products
| Catalog No. | Information |
| CFN98371 | Astilbin Astilbin has insecticidal, antioxidant, antibacterial, and anti-inflammatory activities, it may act as an efficient therapeutic agent for arthritis like cyclosporine A but with less toxicity, its mechanism includes a selective suppression on lymphocyte functions via reducing MMP and NO production. Astilbin can exert an early renal protective role to diabetic nephropathy (DN), inhibit production of transforming growth factor-beta1 (TGF-beta1) and connective tissue growth factor (CTGF).Astilbin also alleviates contact hypersensitivity through a unique mechanism involving a negative cytokine regulation through stimulating IL-10, which is distinct from the immunosuppressant cyclosporin A. |
| CFN95187 | Astin A Astin A has antitumor activity. |
| CFN95188 | Astin B Astin B has antitumor activity. |
| CFN95189 | Astin C Astin C has antitumor activity. |
| CFN98733 | Astragalin Astragalin (kaempferol-3-O-glucoside) is a flavonoid with anti-inflammatory activity, it inhibits the TLR4-mediated NF-κB and mitogen-activated protein kinases signaling pathways. Astragalin ameliorates oxidative stress-associated epithelial eosinophilia and apoptosis through disturbing TLR4-PKCβ2-NADPH oxidase-responsive signaling; it also can be effective in allaying ROS-promoted bronchial fibrosis through inhibiting autophagosome formation in airways. |
| CFN99170 | Astragaloside Astragaloside may protect against brain contusion and neuronal apoptosis after TBI by attenuating microglia activation in male rats. Astragalosides-induced apoptosis in NB4 cells may be associated with down-regulation of the expression of BCL-2 and NF-κB, finally the relative activity of caspase-3 activated. Astragaloside has several pharmacological actions on cardiovascular system, including positive inotropic, anti-arrhythmia and anti-oxidant activities; it also has anti-apoptotic activity, which may contribute to the improvement of clinical outcomes in treating myocarditis with pharmaceutics of Astragalus membranaceus. |
| CFN99172 | Astragaloside I Astragaloside Ι may protect the cerebral tissue against the free radical damage in ischemia and inhibit the activation of BV-2 cells induced by LPS through suppressing the activation of PI3K/Akt/NF-κB pathway. It stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway, which also activates the BMP pathway and RANK pathway. |
| CFN99173 | Astragaloside II Astragaloside II is a potent autophagy inhibitor and multidrug resistance (MDR) reversal agent, which restores chemosensitivity of anticancer agent cisplatin and enhances tumor cell death. It has immunomodulating activity, can trigger T cell activation through regulation of CD45 protein tyrosine phosphatase activity, it induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways. |
| CFN99174 | Astragaloside III Astragaloside III has anti-gastric ulcer effects, and exhibits strong growth-promoting effects in cultured GES-1 cells. Astragaloside III can effectively reduce cancer cell survival in vitro and inhibit the tumor growth in vivo, the potential mechanism is the induction of cell apoptosis signaling pathways, suggests that it provides a new therapeutic tool to treat breast cancer. |
| CFN99171 | Astragaloside IV Astragaloside IV can protect the myocardium against ischemia/reperfusion injury, inhibit adenovirus replication and apoptosis in A549 cells in vitro, has anti-fibrotic effect against systemic sclerosis, and may be useful in ameliorating food-induced metabolic syndrome and membranous nephropathy. It suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. |
